|Have Questions?||Leave a Message or Start an on-line Chat|
The production of the FCGR3A recombinant monoclonal antibody initiates with the acquisition of FCGR3A antibody genes. These genes are then introduced into suitable host cells, which are cultured for synthesizing FCGR3A antibodies using a cell-based expression and translation system. This approach offers numerous advantages, including a substantial improvement in the purity and stability of the resultant FCGR3A recombinant monoclonal antibodies, along with enhancements in antibody affinity and specificity. Subsequent to synthesis, the FCGR3A recombinant monoclonal antibody undergoes purification via affinity chromatography. It is recommended for use in ELISA and IF. This antibody exclusively targets the human FCGR3A protein.
FCGR3A is an important receptor involved in the recognition and response to antibodies, particularly in ADCC and phagocytosis. Its activation on immune cells is a key mechanism for targeting and eliminating infected or abnormal cells and pathogens, contributing to the body's defense against infections and cancer.
There are currently no reviews for this product.